RCTNCT01381484Phase 3 · 2009 · n=70 · Mahidol University Wrinkles
tested Efficacy
result Completed; results not posted
RCTNCT01750346Phase 2 · 2012 · n=8 · National Institute of Neurological Disorders and Stroke (NINDS) Focal Dystonia
tested The Jankovic Blepharospasm Rating Scale at 2 Month
result Terminated before completion
Treatment studies
tested time to return to baseline Jankovic Blepharospasm Rating Scale (JBRS) after BoNT injection
result Trend for longer time to JBRS baseline in active vs placebo (3.7 vs 3.0 months); 4/12 active patients had extension of 3.3–7.1 months; no statistically significant results reported.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested subjective wrinkle assessment (Daniell's classification, Seeman's standard) and objective skin roughness parameters via silicone replica analysis
result Argireline group: 48.9% total anti-wrinkle efficacy vs 0% placebo; all roughness parameters decreased in argireline group (p<0.05); no significant change in placebo group (p>0.05).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested wrinkle improvement (total anti-wrinkle efficiency, wrinkle depth)
result Argireline group: total anti-wrinkle efficiency 48.9%; wrinkle depth notably reduced (P<0.01) vs placebo after 4 weeks twice-daily topical use.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Skin microtopography (cR2, cR3 parameters) and transepidermal water loss (TEWL) at 20, 40, and 60 days
result Acetyl hexapeptide-3 confirmed antiwrinkle activity and significant TEWL reduction. Tripeptide-10 citrulline showed antiwrinkle efficacy. Multiple between-group cR2/cR3 comparisons significant (P<.05) at 20 and 60 days.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Wrinkle improvement (photodamage scoring, Antera 3D image analysis) and skin hydration
result Statistically significant improvements in wrinkle and skin hydration in all groups (p<0.05) on day 29; 50/52 subjects (96.2%) completed. No serious adverse effects.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested wrinkle depth measured by skin topography analysis
result Topical 10% Argireline O/W emulsion reduced wrinkle depth up to 30% after 30 days in healthy women volunteers.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested skin hydration, elasticity, sebum (objective parameters), photographs, investigator clinical assessment, self-image expectation
result Topical 10% argireline gelcream significantly improved skin hydration, elasticity, and sebum values plus self-image in 26 patients with skin disorders; no allergic reactions documented.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested reduction in lateral canthal wrinkle depth/area
result Topical Z. piperitum + acetyl hexapeptide-8 combination improved wrinkles ~14.5% on average; combination showed synergistic tendency vs either agent alone.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Mycobacterium abscessus infection at injection sites (erythema, nodules, abscesses)
result Argireline injection → M. abscessus infection 1 week later; erythema, nodules, abscesses confirmed by culture; resolved after clarithromycin 500mg BID + moxifloxacin 400mg QD for 5 months.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested wrinkle score and TruSkinAge® measured via Visia® camera at baseline and 4 weeks
result Wrinkle scores decreased slightly but non-significantly on both sides (right p=0.060, left p=0.176); no significant difference between Argireline vs non-Argireline sides (p=0.829).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested radiance, fine lines, and wrinkles
result TNP-serum combined with BTX-A improved radiance, reduced fine lines and wrinkles in diverse patients; appears to offer additive effect to BTX-A injections.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested reduction in wrinkle number, length, and area after 28 days
result BMa/AHP-8 facial cream produced greater reduction in wrinkle number, length, and area after 28 days vs AHP-8 monotherapy; in vitro permeation 3.10× higher.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested static and dynamic wrinkle clinical scoring, skin quality (smoothness, radiance, pore size, elasticity, firmness)
result Static wrinkles improved 35%–69% clinical scoring at 12 weeks (p<0.001); dynamic wrinkles 10%–13% (p<0.001); smoothness +30%, radiance +27%, pore -43%, elasticity +33%, firmness +36%.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Skin elasticity and wrinkle parameters
result DAC-SAP/BGP (argireline + DDB + CTX nanoparticles in DES) significantly inhibited Na/Ca channel activity, reduced ACh secretion, and improved skin elasticity and wrinkle parameters in exploratory clinical assessments.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Preclinical / mechanistic research
tested The study of cellular cytotoxicity of argireline - an anti-aging peptide.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Enhanced delivery of hydrophilic peptides in vitro by transdermal microneedle pretreatment.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Fluorous oligoarginines as supra-enhancers for intracellular and transdermal peptide delivery.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.